Endo Pharmaceuticals Holdings Inc. (ENDP, Financial) filed Amended Quarterly Report for the period ended 2008-09-30.
Endo Pharmaceuticals Holdings Inc. through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc. is engaged in the research development sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Endo Pharmaceuticals Holdings Inc. has a market cap of $2.98 billion; its shares were traded at around $23.54 with a P/E ratio of 10.15 and P/S ratio of 2.75. Endo Pharmaceuticals Holdings Inc. had an annual average earning growth of 25.5% over the past 5 years.
Read the The complete Report
More on ENDP:
Gurus buys and sells of ENDP
10-year financial history of ENDP.
Insider buys/sells of ENDP.
Endo Pharmaceuticals Holdings Inc. through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc. is engaged in the research development sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Endo Pharmaceuticals Holdings Inc. has a market cap of $2.98 billion; its shares were traded at around $23.54 with a P/E ratio of 10.15 and P/S ratio of 2.75. Endo Pharmaceuticals Holdings Inc. had an annual average earning growth of 25.5% over the past 5 years.
Highlight of Business Operations:
Read the The complete Report
Gurus who own ENDP
ENDP is in the portfolios of Carl Icahn.More on ENDP:
Gurus buys and sells of ENDP
10-year financial history of ENDP.
Insider buys/sells of ENDP.
